These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. Calò LA; Savica V; Piccoli A; Fusaro M; D'Angelo A; Davis PA Ren Fail; 2011; 33(1):11-4. PubMed ID: 21219199 [TBL] [Abstract][Full Text] [Related]
25. Salivary glands: a new player in phosphorus metabolism. Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917 [TBL] [Abstract][Full Text] [Related]
26. [Salivary phosphate-binding chewing gum--an integrative approach to chronic kidney disease and oral diseases]. Wilczyńska-Borawska M; Borawski J; Stokowska W Przegl Lek; 2011; 68(9):633-6. PubMed ID: 22335015 [TBL] [Abstract][Full Text] [Related]
27. Use of phosphate binders in chronic kidney disease. Ketteler M; Biggar PH Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841 [TBL] [Abstract][Full Text] [Related]
28. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]